License our cutting-edge legal content to strengthen your thought leadership and brand. LexisNexis® and Bloomberg Law are external online distributors of ALM`s extensive collection of current and archived versions of legal news publications. LexisNexis® and Bloomberg Law clients may access and use ALM content, including content from the National Law Journal, The American Lawyer, Legaltech News, New York Law Journal and Corporate Counsel, as well as other sources of legal information. Other companies, such as Alexion Pharmaceuticals Inc., Boston Scientific Corp. and Johnson & Johnson, did not list their chief counsels — Ellen Chiniara, Desiree Ralls-Morrison and Michael Ullmann — as their highest-paid executives in 2019. Alexion said it has paid $470,013 to Judith Reinsdorf, a board member currently serving as legal counsel at Johnson Controls International plc. Johnson & Johnson hopes to begin human testing for its experimental coronavirus vaccine in September. Gilead Sciences Inc., which offers an experimental coronavirus treatment with remdesivir, an antiviral drug it developed to fight Ebola, saw Brett Pletcher, general counsel and executive vice president of corporate affairs, earn more than $5.03 million in 2019. Pletcher, who was hired as general counsel by Gilead, based in Foster City, California, in 2005, earned a salary of $891,000, $1.24 million in non-participating incentive plan compensation and $2.89 million in stock and option bonuses last year. When pharmaceutical companies seek approval of a drug or vaccine from the Food and Drug Administration, general counsel and law firms typically play a limited but crucial role in developing the strategy to be presented to the agency.
A proxy circular filed last week by Bristol-Myers Squibb Co. shows that longtime general counsel Sandra Leung was one of the highest-paid legal directors in the pharmaceutical industry. Bloomberg Law previously reported on the roughly $3.5 million salary package that John Chou, general counsel of AmerisourceBergen Corp., received last year, as well as the $2.62 million and $2.47 million earned by John Griffin and John Jenkins Jr. in their roles as general counsel to medical technology company Hologic Inc. and medical device maker TE Connectivity Ltd. Charles River Laboratories International Inc. – David Johst, $6.57 million ($1.35 million in cash)Liminal BioSciences Inc. – Patrick Sartore, $5.12 million ($842,161); Sartore is now Chief Operating Officer for North America at Liminal and was replaced as General Counsel by Marie Iskra on September 1.
Crispr Therapeutics AG – James Kasinger, $4.22 million ($595,502)Bausch Health Cos. Inc. – Christina Ackermann, $3.38 million ($1.50 million)Baxter International Inc. – Sean Martin, $3.21 million ($1.24 million)Stryker Corp. – Robert Fletcher, $3.15 million ($788,172) GW Pharmaceuticals plc – Douglas Snyder, $2.89 million ($749,283)Fate Therapeutics Inc. – Cindy Tahl, $2.82 million ($525,938)Insmed Inc. – Christine Pellizzari, $2.71 million ($673,400)Theravance Biopharma Inc. – Bradford Shafer, US$2.47 million (US$753,014)AdapthHealth Corp. – Christopher Joyce, US$2.40 million (US$343,750)Agilent Technologies Inc.
– Michael Tang, US$2.34 million (US$927,140)Prothena Corp. plc – Michael Malecek, US$2.29 million (US$492,692)Revolution Medicines Inc. – Margaret „Peg“ Horn, US$2.22 million ($550,525) Halozyme Therapeutics Inc. – Harry Leonhardt, US$1.95 million (US$681,152); Leonhardt verließ das Unternehmen am 3. Januar gemäß dem Proxy Statement von Halozyme und wurde durch General Counsel Masaru Matsuda ersetzt. Hill-Rom Holdings Inc. – Deborah Rasin, US$1.94 million (US$826,515)Aduro Biotech Inc. – Blaine Templeman, US$1.75 million (US$1.02 million)Precision BioSciences Inc. – Dario Scimeca, US$1.71 million (US$254,430)Owens & Minor Inc. – Nicholas Pace, US$1.58 million (US$852,560)Wright Medical Group NV – James Lightman, US$1.57 million (US$699,616)AMN Healthcare Services Inc. – Denise Jackson, US$1.56 million (US$769,054)Arrowhead Pharmaceuticals Inc.
– Patrick O`Brien, US$1.55 million (US$671,744)Acadia Healthcare Co. Inc. – Christopher Howard, US$1.53 million (US$859,692)Kaleido Biosciences Inc. – Jerald Korn, US$1.50 million (US$290,552 Enanta Pharmaceuticals Inc. – Nathaniel Gardiner, $1.49 million ($569,335)West Pharmaceutical Services Inc. – George Miller, $1.49 million ($792,222)Collegium Pharmaceutical Inc. – Shirley Kuhlmann, $1.45 million ($578,454)CryoLife Inc. – Jean Holloway, $1.39 million ($533,876)Lantheus Holdings Inc. – Michael Duffy, $1.30 million ($650,008) PPD Inc. – B. Judd Hartman, $1.26 million ($744,704) Revance Therapeutics Inc. – Caryn McDowell, $1.23 million ($588,489)Osmotica Pharmaceuticals plc – Christopher Klein, $1.23 million ($414,539) Below 32 companies – the last two are related – in the pharmaceutical, medical device, laboratory technology and healthcare sectors, as well as the total compensation they paid to their top corporate lawyers in 2019.
In parentheses is the cash component of each lawyer`s remuneration, a figure derived from the calculation of the annual base salary, cash bonuses and the remuneration of the non-capital incentive scheme. Pharmaceutical company chief counsel working on potential coronavirus treatments were among the highest-paid in the U.S. last year, according to a Bloomberg Law investigation into 2019 proxy circulars filed in recent weeks. AIM ImmunoTech Inc., a company based in Ocala, Florida, known as Hemispherx Biopharma Inc. Until last year`s name change, it signed a contract in Japan in early March to test its flagship immunological stimulant Ampligen as a potential treatment for the coronavirus. A proxy circular filed in 2019 by AIM shows that it paid $430,102 – $333,333 in cash – to Chief Operating Officer and General Counsel Peter Rodino III.